Anne Galy, Ph.D., from Inserm, and co-authors, applied a novel lentivirus-based gene therapy strategy in CD34 + hematopoietic progenitor and stem cells (HSPCs) obtained from cord blood.

Pain and clinical scores were calculated for each patient. Image analysis to calculate area percent for TLR-2 and CD34 immuno-expression was performed. Data was tabulated and statistically analyzed.

We used oligonucleotide-based DNA microarrays to study global gene expression in ten AML+8 patients with +8 as the sole chromosomal abnormality and ten AML-CN patients, as well as seven CD34+ cell ...